Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AXDX
Previous Symbol
CUSIPN/A
Phone520-365-3100
Debt
Debt-to-Equity Ratio1.52
Current Ratio35.26
Quick Ratio33.54
Price-To-Earnings
Trailing P/E Ratio-12.27
Forward P/E Ratio-8.84
P/E GrowthN/A
Sales & Book Value
Annual Sales$4.18 million
Price / Sales184.51
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.14 per share
Price / Book6.65
Profitability
EPS (Most Recent Fiscal Year)($1.16)
Net Income$-64,020,000.00
Net Margins-1,365.75%
Return on Equity-81.76%
Return on Assets-42.90%
Miscellaneous
EmployeesN/A
Outstanding Shares54,200,000
Market Cap$766.91 million
OptionableOptionable
Accelerate Diagnostics (NASDAQ:AXDX) Frequently Asked Questions
What is Accelerate Diagnostics' stock symbol?
Accelerate Diagnostics trades on the NASDAQ under the ticker symbol "AXDX."
How were Accelerate Diagnostics' earnings last quarter?
Accelerate Diagnostics Inc (NASDAQ:AXDX) issued its quarterly earnings data on Tuesday, November, 6th. The medical research company reported ($0.41) earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.41). The medical research company had revenue of $1.36 million for the quarter, compared to analyst estimates of $2.89 million. Accelerate Diagnostics had a negative net margin of 1,365.75% and a negative return on equity of 81.76%. View Accelerate Diagnostics' Earnings History.
When is Accelerate Diagnostics' next earnings date?
What price target have analysts set for AXDX?
4 brokers have issued 1-year price targets for Accelerate Diagnostics' shares. Their forecasts range from $16.00 to $25.00. On average, they anticipate Accelerate Diagnostics' stock price to reach $21.6667 in the next twelve months. This suggests a possible upside of 52.3% from the stock's current price. View Analyst Price Targets for Accelerate Diagnostics.
What is the consensus analysts' recommendation for Accelerate Diagnostics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accelerate Diagnostics in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Accelerate Diagnostics.
Has Accelerate Diagnostics been receiving favorable news coverage?
Headlines about AXDX stock have trended very positive recently, InfoTrie Sentiment reports. The research firm rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Accelerate Diagnostics earned a media sentiment score of 3.9 on InfoTrie's scale. They also gave press coverage about the medical research company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the near term.
Who are some of Accelerate Diagnostics' key competitors?
Some companies that are related to Accelerate Diagnostics include Coherent (COHR), Horiba (HRIBF), Pacific Biosciences of California (PACB), Quanterix (QTRX), Fluidigm (FLDM), Eyepoint Pharmaceuticals (EYPT), Harvard Bioscience (HBIO), HTG Molecular Diagnostics (HTGM), BioNano Genomics (BNGO), Arrayit (ARYC), Aethlon Medical (AEMD), Scientific Industries (SCND), Precipio (PRPO), Pressure Biosciences (PBIO) and PositiveID (PSID).
Who are Accelerate Diagnostics' key executives?
Accelerate Diagnostics' management team includes the folowing people:
- Mr. Lawrence Mehren, Pres, CEO, Director and Interim Head of Europe, Middle East & Africa (Age 52)
- Mr. Steve Reichling, Chief Financial Officer (Age 40)
- Mr. Ron Price, Sr. VP & Head of Commercial Operations - Americas (Age 54)
- Mr. Kurt Reinhardt, Head of Operations
- Dr. Romney M. Humphries Ph.D., D(ABMM), M (ASCP)CM, Chief Scientific Officer
Who are Accelerate Diagnostics' major shareholders?
Accelerate Diagnostics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Credit Suisse AG (6.74%), BlackRock Inc. (3.30%), Vanguard Group Inc. (2.38%), Blair William & Co. IL (1.62%), Chicago Capital LLC (1.16%) and FMR LLC (1.09%). Company insiders that own Accelerate Diagnostics stock include Jack W Schuler, John Patience, Lawrence Mehren, Matthew Strobeck, Steven Reichling and Thomas D Brown. View Institutional Ownership Trends for Accelerate Diagnostics.
Which institutional investors are selling Accelerate Diagnostics stock?
AXDX stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Morgan Stanley, C WorldWide Group Holding A S, TIAA CREF Investment Management LLC, Albion Financial Group UT and Bank of New York Mellon Corp. View Insider Buying and Selling for Accelerate Diagnostics.
Which institutional investors are buying Accelerate Diagnostics stock?
AXDX stock was acquired by a variety of institutional investors in the last quarter, including Griffin Asset Management Inc., Blair William & Co. IL, Credit Suisse AG, FMR LLC, Chicago Capital LLC, BlackRock Inc., Trellus Management Company LLC and AXA. Company insiders that have bought Accelerate Diagnostics stock in the last two years include Jack W Schuler, John Patience, Matthew Strobeck, Steven Reichling and Thomas D Brown. View Insider Buying and Selling for Accelerate Diagnostics.
How do I buy shares of Accelerate Diagnostics?
Shares of AXDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Accelerate Diagnostics' stock price today?
One share of AXDX stock can currently be purchased for approximately $14.23.
How big of a company is Accelerate Diagnostics?
Accelerate Diagnostics has a market capitalization of $766.91 million and generates $4.18 million in revenue each year. The medical research company earns $-64,020,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis.
What is Accelerate Diagnostics' official website?
How can I contact Accelerate Diagnostics?
Accelerate Diagnostics' mailing address is 3950 South Country Club Suite 470, Tucson AZ, 85714. The medical research company can be reached via phone at 520-365-3100 or via email at inve[email protected]
MarketBeat Community Rating for Accelerate Diagnostics (NASDAQ AXDX)
MarketBeat's community ratings are surveys of what our community members think about Accelerate Diagnostics and other stocks. Vote "Outperform" if you believe AXDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
